Skip to main content
CAMBRIDGE NUTRITIONAL SCIENCES PLC logo

CAMBRIDGE NUTRITIONAL SCIENCES PLC — Investor Relations & Filings

Ticker · CNSL ISIN · GB00B1VCP282 LEI · 2138007U9P4BTZTYIR92 IL Manufacturing
Open in API
Filings indexed 532 across all filing types
Latest filing 2020-07-14 Earnings Release
Country GB United Kingdom
Listing IL CNSL

About CAMBRIDGE NUTRITIONAL SCIENCES PLC

https://www.cnsplc.com/

Cambridge Nutritional Sciences PLC is a medical diagnostics company that develops, manufactures, and distributes products focused on promoting a personalised approach to health. The company specialises in a range of tests associated with food sensitivity and gut health. Utilising advanced diagnostic technology, its products are designed for use by healthcare professionals and their patients to identify potential food reactions and guide lifestyle and dietary changes. The company's goal is to enable individuals to improve their long-term health and wellbeing by understanding how their diet may be contributing to various health issues.

Recent filings

Filing Released Lang Actions
Final Results
Earnings Release Classification · 1% confidence The document is titled 'FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2020' and contains detailed financial highlights, operational highlights, a Chairman's Statement, and a Chief Executive's Review. It provides a comprehensive overview of the company's performance for the fiscal year. While it is distributed via an RNS (Regulatory News Service) feed, the content is the actual annual financial results report rather than a mere announcement of the report's availability. Therefore, it is classified as an Annual Report (10-K equivalent for UK-listed companies). FY 2020
2020-07-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings'. This is a regulatory requirement for shareholders to disclose when their voting rights in a company cross certain thresholds. This specific document details a change in shareholding for Omega Diagnostics Group PLC. According to the provided filing definitions, a 'Major Shareholding Notification' (Code: MRQ) is the correct classification for notifications of changes in significant share ownership levels.
2020-07-13 English
Result of General Meeting
Regulatory Filings Classification · 1% confidence The document contains three distinct sections: a declaration of voting results from a General Meeting, a statement on total voting rights, and a detailed report of share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs). While it contains voting results (DVA), the primary substance and the majority of the text are dedicated to the disclosure of director share dealings (DIRS) under the EU Market Abuse Regulation. Given the document's structure as a combined regulatory announcement, 'DIRS' is the most specific and accurate classification for the core transactional data provided.
2020-07-10 English
Notice of Results
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from Omega Diagnostics Group PLC titled 'Notice of Results'. It informs the market that the company will release its financial results on a future date and provides details for an upcoming investor presentation. Per the 'Menu vs Meal' rule, this is an announcement regarding the publication of a report, not the report itself, making it a Report Publication Announcement (RPA).
2020-07-10 English
Result of Open Offer – full take up
Regulatory Filings Classification · 1% confidence The document is an RNS announcement from Omega Diagnostics Group PLC regarding the results of an 'Open Offer' and fundraising activities. It details the number of shares issued, the take-up of the offer, and mentions director participation. This falls under capital raising and financing activities, which is best classified as CAP (Capital/Financing Update).
2020-07-08 English
Approval for sale in India
Regulatory Filings Classification · 1% confidence The document is a news release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces a specific operational update regarding regulatory approval for a product (COVID-19 antibody test) in India. It does not fit into specific categories like financial reports, dividends, or director dealings, and it is not a report publication announcement. Therefore, it falls under the general regulatory announcement category.
2020-07-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.